Merck and Moderna: 99% of Trial Patients Served With Personalized mRNA Vaccine as Shots Near Market

A news report on November 6 says Merck and Moderna have served 99% of trial patients with their personalized mRNA cancer vaccine, with the shots nearing market. Coverage also cites a study showing personalized melanoma vaccines help the immune system attack tumors. Trial phase, exact enrollment and regulatory timing were not given in the feed summary and remain unverified.